JP2024506861A5 - - Google Patents

Info

Publication number
JP2024506861A5
JP2024506861A5 JP2023546560A JP2023546560A JP2024506861A5 JP 2024506861 A5 JP2024506861 A5 JP 2024506861A5 JP 2023546560 A JP2023546560 A JP 2023546560A JP 2023546560 A JP2023546560 A JP 2023546560A JP 2024506861 A5 JP2024506861 A5 JP 2024506861A5
Authority
JP
Japan
Prior art keywords
use according
pharmaceutically acceptable
cns
acceptable salt
sequestering agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506861A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014695 external-priority patent/WO2022165407A1/en
Publication of JP2024506861A publication Critical patent/JP2024506861A/ja
Publication of JP2024506861A5 publication Critical patent/JP2024506861A5/ja
Pending legal-status Critical Current

Links

JP2023546560A 2021-02-01 2022-02-01 物質使用障害の治療のための隔離化合物及びその使用 Pending JP2024506861A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144441P 2021-02-01 2021-02-01
US63/144,441 2021-02-01
PCT/US2022/014695 WO2022165407A1 (en) 2021-02-01 2022-02-01 Sequestration compounds for treatment of substance use disorder and uses thereof

Publications (2)

Publication Number Publication Date
JP2024506861A JP2024506861A (ja) 2024-02-15
JP2024506861A5 true JP2024506861A5 (https=) 2025-02-06

Family

ID=82654907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546560A Pending JP2024506861A (ja) 2021-02-01 2022-02-01 物質使用障害の治療のための隔離化合物及びその使用

Country Status (11)

Country Link
US (1) US12569478B2 (https=)
EP (1) EP4284506A4 (https=)
JP (1) JP2024506861A (https=)
KR (1) KR20230167020A (https=)
CN (1) CN117858728A (https=)
AU (1) AU2022213437A1 (https=)
BR (1) BR112023015462A2 (https=)
CA (1) CA3207013A1 (https=)
IL (1) IL304837A (https=)
MX (1) MX2023009055A (https=)
WO (1) WO2022165407A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020245535B2 (en) 2019-03-26 2022-06-30 Pinova Therapeutics Inc. Devices and methods for delivering pharmaceutical compositions
CA3207013A1 (en) 2021-02-01 2022-08-04 Xinhua Li Sequestration compounds for treatment of substance use disorder and uses thereof
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
AU2024303746A1 (en) * 2023-06-16 2026-01-22 Clear Scientific, Inc. Sequestrant compounds for alpha 2 adrenergic agonists
WO2025184478A1 (en) * 2024-03-01 2025-09-04 Temple University-Of The Commonwealth System Of Higher Education Reversal agents for ultra-potent synthetic opioid-induced overdose and respiratory depression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375149T1 (de) * 2003-07-25 2007-10-15 Euro Celtique Sa Behandlung von entzug
ES2702848T3 (es) * 2011-02-23 2019-03-05 Coeruleus Ltd Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
CA2875384A1 (en) * 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10874358B2 (en) * 2015-12-22 2020-12-29 Joseph Insler Method and device for automatic identification of an opioid overdose and injection of an opioid receptor antagonist
IL312012A (en) * 2016-11-18 2024-06-01 Opiant Pharmaceuticals Inc Compositions and methods for the treatment of opioid overdose
EP3833346A4 (en) * 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC Compositions for opiate and opioid prevention and reversal, and methods of their use
CA3134674A1 (en) * 2019-04-04 2020-10-08 Intra-Cellular Therapies, Inc. Methods of treating neuropathic pain
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
CA3207013A1 (en) 2021-02-01 2022-08-04 Xinhua Li Sequestration compounds for treatment of substance use disorder and uses thereof

Similar Documents

Publication Publication Date Title
JP2024506861A5 (https=)
EP1244447B1 (en) Novel methods and compositions involving opioids and antagonists thereof
US9649282B2 (en) Diversion- and/or abuse-resistant compositions and methods for making the same
Goodman et al. Mu opioid receptor antagonists: recent developments
Lewis et al. The orvinols and related opioids-high affinity ligands with diverse efficacy profiles
EP2506712B1 (en) Morphinan derivatives for the treatment of drug overdose
US20010047005A1 (en) Novel methods and compositions involving opioids and antagonists thereof
JP2003528819A5 (https=)
CA2336902C (en) Topical compositions comprising an opioid analgesic and an nmda antagonist
JP2010511683A5 (https=)
JP2008534564A5 (https=)
JP2004515455A (ja) オピオイドアンタゴニスト組成物および投薬形態
KR102082529B1 (ko) 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
WO2008045556A2 (en) Novel synergistic opioid-cannabinoid codrug for pain management
CN109641849B (zh) 氘代右美沙芬的合成方法
JP2007508325A5 (https=)
Kamerling et al. Narcotic analgesics, their detection and pain measurement in the horse: a review
JP2003520234A (ja) 薬物中毒の治療方法
WO2009070733A1 (en) Peripheral phenolic opioid antagonist
JP5089687B2 (ja) アルコール依存症または薬物依存症の予防または治療剤
Casy The structure of narcotic analgesic drugs
JP2020536892A5 (https=)
US20050113401A1 (en) Treatment of chemical dependency with substantially nonaddicting normorphine and norcodeine derivatives
JP2007503473A5 (https=)
IL273904B2 (en) Medicinal resin components and methods for their production and use